7+3 chemotherapy

The 7+3 chemotherapy regimen is a treatment approach primarily used for acute myeloid leukemia (AML). It involves giving two chemotherapy drugs: cytarabine (ara-C) continuously for 7 days and an anthracycline (like daunorubicin) for the first 3 days. The combination aims to destroy leukemia cells in the bone marrow, improve the chance of remission, and allow the healthy blood cells to recover. This approach balances effectiveness with manageable side effects and is a standard initial therapy for many AML patients.